Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON23324
NL-OMON23324Not yet recruitingNot Applicable

An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular response.

SKION/DCOG (Stichting Kinderoncologie Nederland)Leyweg 2992545CJ Den Haag0 sites60 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
60
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

/A

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •1. Pediatric CML patients treated with Imatinib having achieved and maintained complete molecular remission for at least 2 years;
  • •2. Informed consent needs to be signed.

Exclusion Criteria

  • •Non-CML patients, or CML patients with complete cytogenetic reponse but with a moderate molecular response.

Investigators

Sponsor
SKION/DCOG (Stichting Kinderoncologie Nederland)Leyweg 2992545CJ Den Haag

Similar Trials

Completed
Phase 4
An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular responsechronic myeloid leukemia10024324
NL-OMON39021Stichting Kinderoncologie Nederland6
Active, not recruiting
Not Applicable
An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular response(STOPIMAPED)Chronic Myeloid Leukemia pediatric patients treated with Imatinib having achieved and maintained complete molecular remission for at least 2 years.
EUCTR2011-006239-44-NLDutch Childhood Oncology Group60
Recruiting
Phase 1
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastinestandard risk ALK-positive anaplastic large cell lymphoma (ALCL)
CTIS2022-501454-11-00GPOH gGmbH132
Recruiting
Phase 3
International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
DRKS00023541Gesellschaft für pädiatrische Hämatologie und Onkologie (GPOH) gGmbH106
Not yet recruiting
Phase 3
International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine.
NL-OMON51961German Pediatric Oncology Group (GPOH) gGmbH10